Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.82M | 11.57M | 12.31M | 13.63M | 14.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.25M | 53.70M | 55.26M | 55.60M | 75.80M |
| Operating Income | -57.25M | -53.70M | -55.26M | -55.60M | -75.80M |
| Income Before Tax | -53.70M | -49.66M | -50.71M | -50.61M | -70.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.70M | -49.66M | -50.71M | -50.61M | -70.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.70M | -49.66M | -50.71M | -50.61M | -70.06M |
| EBIT | -57.25M | -53.70M | -55.26M | -55.60M | -75.80M |
| EBITDA | -57.18M | -53.62M | -55.18M | -55.52M | -75.72M |
| EPS Basic | -0.81 | -0.75 | -0.86 | -0.86 | -1.07 |
| Normalized Basic EPS | -0.55 | -0.51 | -0.54 | -0.54 | -0.74 |
| EPS Diluted | -0.81 | -0.75 | -0.86 | -0.86 | -1.07 |
| Normalized Diluted EPS | -0.55 | -0.51 | -0.54 | -0.54 | -0.74 |
| Average Basic Shares Outstanding | 61.49M | 60.47M | 59.20M | 59.08M | 59.02M |
| Average Diluted Shares Outstanding | 61.49M | 60.47M | 59.20M | 59.08M | 59.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |